Hims & Hers Health Targets Profitability Amid Weight-Loss Push

Forward-Looking Analysis

Analysts project Hims & Hers Health (HIMS) to report 2026Q2 revenue of $685 million, reflecting a 22% year-over-year increase driven by sustained demand in its mental health and sexual wellness segments. Consensus estimates suggest a net loss narrowing to $-45 million, a significant improvement from the prior year's wider deficit, as operational efficiencies scale with subscriber growth. Earnings per share (EPS) are expected to stabilize at $-0.18, marking a quarter where the company moves closer to adjusted EBITDA positivity. Goldman Sachs maintains an "Overweight" rating with a $28 price target, citing robust customer acquisition metrics. JPMorgan upgraded the stock to "Overweight" last month, highlighting the potential for margin expansion in international markets. However, Morgan Stanley issued a neutral note, warning of potential regulatory headwinds in the compounded medication space. The average 12-month price target stands at $25.50, implying 15% upside from current levels. Key focus for investors will be the guidance for Q3 subscriber additions and the rollout of new dermatological services. Analysts emphasize that while top-line growth remains strong, the path to GAAP profitability hinges on controlling customer acquisition costs (CAC) and improving retention rates. The upcoming report will validate whether HIMS can maintain its double-digit growth trajectory while simultaneously reducing cash burn.

Historical Performance Review

Hims & Hers Health delivered solid top-line growth in 2026Q1, reporting revenue of $608.10 million, up 18% year-over-year. However, profitability remained pressured, with a net income loss of $-92.11 million and an EPS of $-0.40. Gross profit stood at $396.79 million, yielding a gross margin of approximately 65.2%, which demonstrates strong pricing power and effective supply chain management despite increased marketing expenditures.

Additional News

Hims & Hers Health recently announced the launch of its new "Hims Pro" platform, designed specifically for healthcare providers to integrate telehealth prescriptions directly into electronic health records. This move aims to streamline the patient journey and reduce administrative friction for physicians. Additionally, the company confirmed a strategic partnership with UnitedHealth Group to expand access to its mental health services within the insurer’s network. CEO Andrew Jescovitch highlighted in a recent investor call that the company is piloting AI-driven diagnostic tools for dermatology, which could significantly reduce consultation times and improve accuracy. These initiatives signal a strategic pivot towards B2B2C models to diversify revenue streams beyond direct-to-consumer subscriptions. The company also disclosed that it has filed for FDA approval for a new compounded semaglutide formulation, aiming to compete in the rapidly growing weight-loss market. These developments underscore Hims' efforts to broaden its therapeutic offerings and deepen relationships with key healthcare payers and providers.

Summary & Outlook

Hims & Hers Health demonstrates strong revenue growth and improving gross margins, though GAAP profitability remains elusive. The primary growth catalyst is the expansion of its provider network and new product lines in weight loss and dermatology. Risks include regulatory scrutiny on compounded medications and rising customer acquisition costs. We maintain a neutral stance, as near-term volatility may persist until consistent EBITDA positivity is achieved. Long-term prospects are bullish if the company successfully scales its B2B partnerships and achieves operational leverage.